You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Endorsement of the 2018 American Society of Clinical Oncology Treatment of Malignant Pleural Mesothelioma Guideline

Version: 3 ID: GL END 7-14v3 Dec 2018
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
M. de Perrot, E.T. Vella, P. Bradbury, J. Cho, C. Dennie, J. Goffin, R. MacRae, D. Maziak, M. Tsao, Y.C. Ung, P.M. Ellis, Lung Cancer Disease Site Group

Guideline Objective

The objective of this guideline is to provide recommendations on the most appropriate management of patients with malignant pleural mesothelioma. Our recommendations are based on the 2018 American Society of Clinical Oncology (ASCO) guideline on the treatment of malignant pleural mesothelioma.

Patient Population

This guideline targets adult patients with malignant pleural mesothelioma.

Intended Guideline Users

The intended users of this guideline are medical, surgical, and radiation oncologists; oncology nurses and physician assistants; pulmonologists; radiologists; pathologists; and general practitioners managing patients with malignant pleural mesothelioma.

Research Question

Which treatment strategy leads to the greatest benefit and least adverse effects for patients with malignant pleural mesothelioma?


pdf download Full Report (PDF) (409.53 KB)